Key result
Higher GPD1L expression linked to ~40% lower mortality and recurrence risk in CRC patients.
Why the study?
Colorectal cancer has high global incidence and mortality, and identifying potential biomarkers and therapeutic targets is needed to improve early diagnosis, treatment efficacy, and prognosis.
Does GPD1L expression level predict prognosis and regulate cell proliferation, migration, and invasion in colorectal cancer?
Cohort (n=215)
No
Does GPD1L expression level predict prognosis and regulate cell proliferation, migration, and invasion in colorectal cancer?
GPD1L is significantly down-regulated in colorectal cancer, and its low expression serves as an independent predictor of poor overall and recurrence-free survival, while its knockdown promotes CRC cell proliferation and invasion in vitro.
Answers are grounded in this paper and cite their sources.
Supports GPD1L as potential prognostic biomarker in colorectal cancer; hypothesis-generating and should not yet alter practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a cohort in Colorectal cancer (n=215). GPD1L was evaluated on Overall survival (OS) and recurrence-free survival (RFS) (HR 0.602, 95% CI 0.420–0.865, p=0.005). GPD1L expression levels are significantly associated with improved overall survival and recurrence-free survival in colorectal cancer patients.
Synapse has enriched 10 related papers. Consider them for comparative context: